Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System

NCT ID: NCT05291507

Last Updated: 2026-01-15

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 34 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-01-23
• Study Completion Date: 2028-08-31

Brief Summary

This is an open-label, single arm, single center, non-randomized feasibility study of the Muse MRgFUS System in subjects with breast cancer. Subjects will undergo partial ablation of half (≤50%) of one of their tumors (if multifocal or multicentric disease) followed by surgical resection per standard of care. The partial tumor ablation design will ensure that no information is lost that would impact the subject's standard of clinical care. Because current care often includes testing on the tumor, retaining a portion of viable tumor is advised by the clinical team. To ensure viable tissue confirmation, patients will be enrolled in two cohorts as described in the protocol. The investigators will use imaging correlation, histological evaluation, and subject reported outcomes to assess the safety, tolerability, and efficacy of the Muse MRgFUS System. This proposed study will adhere to the guidelines of subjects receiving a timely tumor resection after diagnosis. All subjects will undergo the definitive procedure of surgical resection per standard of care. Surgical resection cannot be delayed as a result of the ablation and should occur within 6 weeks after the decision to proceed with surgical resection. In cases where a surgery may occur outside of the 6 week window, prior approval from the external DSMC should be obtained. While MRgFUS ablation is designed to be a breast-conserving technique, the investigators will enroll patients that are undergoing any surgical resection, including both lumpectomy or mastectomy. Both surgical procedures will allow assessment of the defined primary, secondary and exploratory objectives.

Conditions

Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Muse MRgFUS System

Subjects will undergo partial ablation of half (≤50%) of one of their tumors (if multifocal or multicentric disease) followed by surgical resection per standard of care.

Group Type: EXPERIMENTAL

Muse MRgFUS System

Intervention Type: DEVICE

The intended use of the device is to thermally ablate breast tissue under magnetic resonance image guidance. The thermal ablation is performed non-invasively using extracorporeal focused ultrasound.

Interventions

Muse MRgFUS System

The intended use of the device is to thermally ablate breast tissue under magnetic resonance image guidance. The thermal ablation is performed non-invasively using extracorporeal focused ultrasound.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Subject is able to speak and understand English.
• Female subjects 18 years of age or older with invasive breast cancer undergoing surgery
• ECOG < 2.
• ASA (American Society of Anesthesiologists) Physical Status Classification Scale assessment of I-II.
• Adequate breast size for MUSE device assessed by physician prior to study enrollment.
• Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
• Adequate Renal Function defined as an eGFR > 30 mL/min/1.73.
• Female subjects of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1.
• Negative pregnancy test or evidence of post-menopausal status or evidence of permanent surgical sterilization (i.e. bilateral oophorectomy, bilateral salpingectomy, or hysterectomy). The post-menopausal status will be defined as having been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply:

• Women < 50 years of age:

---Amenorrhoeic for ≥ 12 months following cessation of exogenous hormonal treatments; and

----Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution.

• Women ≥ 50 years of age:

• Amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments; or
• Had radiation-induced menopause with last menses >1 year ago; or
• Had chemotherapy-induced menopause with last menses >1 year ago.

Exclusion Criteria

• Receiving other investigational agents at the time of study registration.
• Prior systemic anti-cancer therapy or any investigational therapy for neoadjuvant treatment of breast cancer.
• Prior radiation therapy to the ipsilateral breast or radiation whose field(s) encompassed the breast within which the current diagnosis of cancer is made.
• The diagnosis of another malignancy within ≤ 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and/or will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, or bladder or of the cervix). Low risk malignancies may be allowed after discussion with PI and medical monitor.
• Women with breast implants
• Pregnant or lactating women
• Inability to lie prone for 90 minutes as reported by patient or determined by investigator assessment.
• Known prior adverse reaction or allergy to commonly used sedatives (i.e. versed, propofol) (NCI CTCAE v5.0 Grade ≥ 3).
• Known prior adverse reaction or allergy to gadolinium contrast (NCI CTCAE v5.0 Grade ≥ 3).
• Contraindication to MRI as determined by treating physician or patient response on MRI patient history and safety questionnaire (Appendix 4)
• Medical, psychiatric, cognitive, or other conditions in the opinion of the investigator that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.

• Patient's tumor is grade 3 as determined in consultation with pathologist and treating physician.
• The amount of invasive tumor in the core biopsy specimen is small as determined in consultation with pathologist and treating physician.
• Core biopsy result is equivocal for HER2 after testing by both in situ hybridization and immunohistochemistry.
• There is doubt about the handling of the core biopsy specimen (long ischemic time, short time in fixative, different fixative), or the test is suspected by the pathologist to be negative on the basis of testing error.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

University of Utah

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Cindy Matsen, MD

Role: PRINCIPAL_INVESTIGATOR

Huntsman Cancer Institute

Locations

Huntsman Cancer Institute at University of Utah

Salt Lake City, Utah, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Janna Espinosa

Role: CONTACT

janna.espinosa@hci.utah.edu

801-585-0571

Facility Contacts

Janna Espinosa

Role: primary

janna.espinosa@hci.utah.edu

801-585-0571

Other Identifiers

HCI148669

Identifier Type: -

Identifier Source: org_study_id